… to the discovery of brain and blood metabolites associated with pathology and progression
of AD (Fig 1). (1) Identifying a brain metabolite signature of AD: in this phase of the study, we …

… If the current trend continues, the cases of Alzheimer's disease will increase four times in the
… distribution of the pathological changes in the neocortex in alzheimer disease. Proc. Natl. …

… , the phase of MCI ends with a marked decline in cognitive function as the disease pathology
… Is the Subject Area "Alzheimer's disease diagnosis and management" applicable to this …

… pathophysiological signatures of Alzheimer’s disease pathology versus frontotemporal lobar
degeneration (FTLD). For example, transgenic rodent models of Alzheimer’s disease have …

… The role of telomerase protein TERT in Alzheimer’s disease and in tau-related pathology in
… Telomere shortening reduces Alzheimer’s disease amyloid pathology in mice. Brain 134(Pt …

… Structural abnormalities in these regions represent a marker of AD pathology, so-called “AD-signature”
[134,135]. The regions have been previously described as the Default Mode …

… (signature 1 is the Alzheimer disease [AD] signature [red]; signature 2 is the healthy signature
[… in more than one-third of cognitively normal subjects suggests that AD pathology is active …

… tau pathology at different stages of AD. Although we identified commonly regulated proteins
and pathways during disease … In addition, a distinct proteomic signature was found between …

… In order to establish that the identified gene networks, particularly the human-related disease
signatures, were not only temporally but also regionally associated with Aβ pathology LCM …

… decline in Alzheimer’s disease (AD). However, the molecular signatures that distinguish …
identified both shared and cell-type-specific signatures. NFT-bearing neurons shared a marked …